Piperacillin 4gm + Tazobactam 0.5gm

Tazocruz 4.5 Injection is a premium broad-spectrum antibiotic formulation brought to you by Amista Labs, a pharmaceutical company dedicated to the “Quest of Better Health.” As a critical care medication, Tazocruz 4.5 is designed to combat severe and resistant bacterial infections. It belongs to the category of penicillin antibiotics combined with beta-lactamase inhibitors, making it a powerful weapon in the treatment of polymicrobial infections in hospital and clinical settings.

Amista Labs ensures that this product meets the highest international standards of safety and efficacy, evidenced by the company’s accreditations, including WHO GMP (Good Manufacturing Practice), GLP (Good Laboratory Practice), and ISO 9001:2015 certification.

Composition and Mechanism of Action

Each vial of Tazocruz 4.5 Injection contains:

• Piperacillin Sodium IP equivalent to Piperacillin 4gm

• Tazobactam Sodium IP equivalent to Tazobactam 0.5gm

The efficacy of Tazocruz 4.5 lies in its potent dual-action composition. Each vial contains a lyophilized powder consisting of:

• Piperacillin (4gm): An extended-spectrum penicillin antibiotic that works by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the cell to rupture and die.

• Tazobactam (0.5gm): A beta-lactamase inhibitor. Many resistant bacteria produce an enzyme called beta-lactamase, which breaks down antibiotics like Piperacillin, rendering them ineffective. Tazobactam acts as a “bodyguard” for the Piperacillin; it irreversibly binds to and neutralizes these enzymes, allowing the Piperacillin to do its job effectively.

This synergistic combination (Total strength: 4.5gm) extends the spectrum of Piperacillin to include bacteria that would otherwise be resistant to it.

Therapeutic Indications (Usage)

According to the clinical profile provided by Amista Labs, Tazocruz 4.5 is indicated for the treatment of moderate to severe infections caused by susceptible strains of microorganisms. Key applications include:

• Severe Bacterial Infections & Sepsis: Tazocruz is a frontline defense against sepsis (blood poisoning), a life-threatening reaction to an infection. It is widely used in ICUs to stabilize patients battling systemic bacterial attacks.

• Nosocomial Pneumonia: It is highly effective in managing hospital-acquired pneumonia, a common and dangerous infection affecting patients on ventilators or with compromised immune systems.

• Intra-abdominal Infections: The injection is frequently prescribed for complicated abdominal issues such as appendicitis (complicated by rupture or abscess) and peritonitis.

• Skin and Soft Tissue Infections: It treats complicated skin infections, including cellulitis, cutaneous abscesses, and diabetic foot infections where polymicrobial presence is suspected.

• Urinary Tract Infections (UTIs): Tazocruz 4.5 manages complicated UTIs that have not responded to first-line antibiotics, ensuring the infection does not spread to the kidneys.

• Gynecological Infections: It is effective in treating postpartum endometritis and pelvic inflammatory disease (PID).

Quality Assurance and Packaging

Amista Labs prioritizes patient safety through rigorous quality control.

• Certifications: The product is manufactured in facilities that adhere to WHO-GMP and ISO standards, ensuring sterility, potency, and consistency in every batch.

• Packaging: The product comes in a sterile box containing a glass vial with the dry powder and typically includes a solvent (Sterile Water for Injection) for reconstitution.

• Economics: With an MRP of 419.34/-, Tazocruz 4.5 offers a cost-effective solution for high-grade antibiotic therapy compared to many innovator brands, making critical care more accessible.

Dosage and Administration

• Route: Intravenous (IV) use only.

• Reconstitution: The powder must be reconstituted with the appropriate volume of diluent (e.g., Sodium Chloride or Dextrose injection) before administration.

• Dosage: The standard adult dose is usually 4.5 gm every 6 to 8 hours, depending on the severity of the infection and the patient’s renal function. (Note: Dosage should always be determined by a qualified physician).